Menu
Search
|

Menu

Close

Search

Close
X

Mesoblast Ltd MESO.OQ (NASDAQ Stock Exchange Global Select Market)

▼
5.86 USD
-0.20 (-3.30%)
As of Jun 22
chart
Previous Close 6.06
Open 6.11
Volume 20,325
3m Avg Volume 13,158
Today’s High 6.11
Today’s Low 5.79
52 Week High 8.48
52 Week Low 4.75
Shares Outstanding (mil) 94.83
Market Capitalization (mil) 542.32
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

VIEW MORE
∨
ADVERTISEMENT

RECOMMENDATION

▼
Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
16
FY17
2
FY16
43
FY15
35
EPS (USD)
FY18
-0.210
FY17
-0.199
FY16
-0.019
FY15
-0.512
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.14
Price to Sales (TTM)
vs sector
33.46
8.17
Price to Book (MRQ)
vs sector
1.00
4.30
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
5.65
17.55
LT Debt to Equity (MRQ)
vs sector
5.65
13.12
Return on Investment (TTM)
vs sector
-19.31
13.10
Return on Equity (TTM)
vs sector
-22.94
15.09

EXECUTIVE LEADERSHIP

Brian Jamieson
Independent Non-Executive Chairman of the Board, Since 2007
Salary: $250,000.00
Bonus: --
Silviu Itescu
Chief Executive Officer, Executive Director, Since 2014
Salary: $1,010,000.00
Bonus: $757,500.00
William Burns
Vice Chairman of the Board, Since 2016
Salary: $167,208.00
Bonus: --
Joshua Muntner
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Peter Howard
General Counsel, Corporate Executive, Since 2011
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

L 38 55 Collins St
MELBOURNE   VIC   3000
Phone: +613.96396036
Site: www.mesoblast.com/

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

SPONSORED STORIES